Roboz, Gail J

Publications

Sort by

Co-Author Network

selected publications

Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients. Leukemia. 2026 Article GET IT
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026 Information Resource GET IT
Times cited: 14
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy. Blood advances. 2026 Academic Article GET IT
Times cited: 1
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial. British journal of haematology. 2025 Academic Article GET IT
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee. The Lancet. Oncology. 2025 Information Resource GET IT
Times cited: 3
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. Blood advances. 2025 Academic Article GET IT
Times cited: 7
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDS. bioRxiv : the preprint server for biology. 2025 Article GET IT
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms. Archives of pathology & laboratory medicine. 2025 Academic Article GET IT
Times cited: 2
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Academic Article GET IT
Times cited: 21
Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response. Haematologica. 2025 Academic Article GET IT
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. HemaSphere. 2025 Academic Article GET IT
Times cited: 6
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. Cancer. 2025 Information Resource GET IT
Times cited: 6
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. British journal of haematology. 2025 Academic Article GET IT
Times cited: 3
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. Blood neoplasia. 2025 Academic Article GET IT
Times cited: 3
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood cancer journal. 2025 Academic Article GET IT
Times cited: 11
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Information Resource GET IT
How I use maintenance therapy in acute myeloid leukemia. Blood. 2025 Article GET IT
Times cited: 6
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future oncology (London, England). 2025 Academic Article GET IT
Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance). Blood advances. 2025 Academic Article GET IT
Times cited: 1
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of hematology & oncology. 2025 Academic Article GET IT
Times cited: 11
High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia. Leukemia & lymphoma. 2025 Academic Article GET IT
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia. The Lancet. Haematology. 2024 Information Resource GET IT
Times cited: 4
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet. Haematology. 2024 Information Resource GET IT
Times cited: 24
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2024 Information Resource GET IT
Times cited: 10
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors). Transplantation and cellular therapy. 2024 Academic Article GET IT
Times cited: 1
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood advances. 2024 Academic Article GET IT
Times cited: 42
Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality. Cancer. 2024 Academic Article GET IT
Times cited: 10
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood advances. 2024 Academic Article GET IT
Times cited: 19
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS). HemaSphere. 2024 Information Resource GET IT
Times cited: 5
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood advances. 2024 Academic Article GET IT
Times cited: 10
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). Leukemia & lymphoma. 2024 Academic Article GET IT
Times cited: 10
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood advances. 2024 Academic Article GET IT
Times cited: 26
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leukemia research. 2024 Academic Article GET IT
Times cited: 2
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clinical lymphoma, myeloma & leukemia. 2024 Academic Article GET IT
Times cited: 6
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study. Blood advances. 2024 Academic Article GET IT
Times cited: 1
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. The Lancet. Haematology. 2024 Academic Article GET IT
Times cited: 80
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. British journal of haematology. 2023 Academic Article GET IT
Times cited: 2
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023 Article GET IT
Times cited: 1
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Haematologica. 2023 Article GET IT
Times cited: 2
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood advances. 2023 Academic Article GET IT
Times cited: 20
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. American journal of hematology. 2023 Academic Article GET IT
Times cited: 25
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood reviews. 2023 Information Resource GET IT
Times cited: 23
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023 Academic Article GET IT
Times cited: 48
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression. Leukemia & lymphoma. 2023 Academic Article GET IT
Times cited: 9
Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements. Pathobiology : journal of immunopathology, molecular and cellular biology. 2023 Academic Article GET IT
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Blood cancer journal. 2023 Article GET IT
Times cited: 1
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood advances. 2023 Academic Article GET IT
Times cited: 10
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood advances. 2023 Academic Article GET IT
Times cited: 62
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood advances. 2023 Academic Article GET IT
Times cited: 33
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological oncology. 2023 Academic Article GET IT
Times cited: 16
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplantation and cellular therapy. 2023 Academic Article GET IT
Times cited: 9
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. The Lancet. Haematology. 2023 Academic Article GET IT
Times cited: 78
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023 Academic Article GET IT
Times cited: 85
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood reviews. 2023 Information Resource GET IT
Times cited: 16
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2023 Academic Article GET IT
Times cited: 14
Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia. American journal of hematology. 2023 Article GET IT
Times cited: 6
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 Academic Article GET IT
Times cited: 60
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. American journal of hematology. 2023 Article GET IT
Times cited: 12
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 2022 Academic Article GET IT
Times cited: 3
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 Article GET IT
Times cited: 27
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022 Academic Article GET IT
Times cited: 40
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Blood cancer journal. 2022 Article GET IT
Times cited: 1
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leukemia research. 2022 Academic Article GET IT
Times cited: 17
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM evidence. 2022 Academic Article GET IT
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood. 2022 Academic Article GET IT
Times cited: 33
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood advances. 2022 Academic Article GET IT
Times cited: 33
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nature communications. 2022 Academic Article GET IT
Times cited: 61
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022 Academic Article GET IT
Times cited: 63
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 2
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021 Information Resource GET IT
Times cited: 634
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia & lymphoma. 2021 Article GET IT
Times cited: 24
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica. 2021 Academic Article GET IT
Times cited: 12
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 18
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Journal of hematology & oncology. 2021 Academic Article GET IT
Times cited: 18
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 149
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 19
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 33
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 4
Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Article GET IT
Times cited: 3
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 29
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific reports. 2021 Academic Article GET IT
Times cited: 14
Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]. Leukemia research. 2021 Article GET IT
Risk factors for multi-joint disease in patients with glucocorticoid-induced osteonecrosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2021 Academic Article GET IT
Times cited: 12
Oral Azacitidine Maintenance for Acute Myeloid Leukemia. Reply. The New England journal of medicine. 2021 Article GET IT
Times cited: 2
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia. 2021 Academic Article GET IT
Times cited: 14
AML and the art of remission maintenance. Blood reviews. 2021 Information Resource GET IT
Times cited: 25
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia. 2021 Information Resource GET IT
Times cited: 74
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood cancer journal. 2021 Academic Article GET IT
Times cited: 11
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leukemia research. 2021 Information Resource GET IT
Times cited: 35
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. Journal of hematology & oncology. 2021 Academic Article GET IT
Times cited: 69
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 33
BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. 2021 Academic Article GET IT
Times cited: 29
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 422
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 374
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer medicine. 2020 Academic Article GET IT
Times cited: 32
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. International journal of laboratory hematology. 2020 Academic Article GET IT
Times cited: 5
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood advances. 2020 Academic Article GET IT
Times cited: 5
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Leukemia & lymphoma. 2020 Article GET IT
Times cited: 3
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 19
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 Academic Article GET IT
Times cited: 17
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 Academic Article GET IT
Times cited: 190
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 19
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect^® MDS/AML Disease Registry. EJHaem. 2020 Academic Article GET IT
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2020 Academic Article GET IT
Times cited: 79
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020 Academic Article GET IT
Times cited: 73
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. The Lancet. Haematology. 2020 Information Resource GET IT
Times cited: 55
Mapping Local Biospecimen Records to the OMOP Common Data Model. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2020 Academic Article GET IT
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 Information Resource GET IT
Times cited: 196
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood advances. 2020 Academic Article GET IT
Times cited: 177
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood advances. 2020 Academic Article GET IT
Times cited: 41
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. British journal of haematology. 2020 Academic Article GET IT
Times cited: 17
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harbor perspectives in biology. 2020 Information Resource GET IT
Times cited: 37
Clonal Hematopoiesis and Premalignant Diseases. Cold Spring Harbor perspectives in medicine. 2020 Information Resource GET IT
Times cited: 18
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clinical lymphoma, myeloma & leukemia. 2020 Academic Article GET IT
Times cited: 6
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2020 Academic Article GET IT
Times cited: 86
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. The Lancet. Haematology. 2020 Academic Article GET IT
Times cited: 99
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Academic Article GET IT
Times cited: 83
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 12
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & lymphoma. 2020 Article GET IT
Times cited: 19
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Academic Article GET IT
Times cited: 330
The therapeutic landscape for cells engineered with chimeric antigen receptors. Nature biotechnology. 2020 Academic Article GET IT
Times cited: 205
Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer cell. 2019 Academic Article GET IT
Times cited: 54
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2019 Academic Article GET IT
Times cited: 35
Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. International journal of surgical pathology. 2019 Article GET IT
Times cited: 1
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 56
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clinical epigenetics. 2019 Academic Article GET IT
Times cited: 25
Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best practice & research. Clinical haematology. 2019 Information Resource GET IT
Times cited: 22
Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. Neoplasia (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 16
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 39
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019 Academic Article GET IT
Times cited: 97
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. The Lancet. Haematology. 2019 Academic Article GET IT
Times cited: 85
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nature nanotechnology. 2019 Academic Article GET IT
Times cited: 292
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 592
Clonal Hematopoiesis and therapy related MDS/AML. Best practice & research. Clinical haematology. 2019 Information Resource GET IT
Times cited: 27
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood advances. 2018 Academic Article GET IT
Times cited: 47
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2018 Academic Article GET IT
Times cited: 282
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 4
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer. 2018 Academic Article GET IT
Times cited: 12
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. American journal of hematology. 2018 Academic Article GET IT
Times cited: 37
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood advances. 2018 Academic Article GET IT
Times cited: 124
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Academic Article GET IT
Times cited: 223
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood advances. 2018 Academic Article GET IT
Times cited: 89
Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature medicine. 2018 Academic Article GET IT
Times cited: 530
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 2018 Article GET IT
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1304
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. Clinical lymphoma, myeloma & leukemia. 2018 Academic Article GET IT
Times cited: 17
Evaluating Generalizability of a Biospecimen Informatics Approach: Support for Local Requirements and Best Practices. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2018 Academic Article GET IT
Times cited: 51
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. 2018 Academic Article GET IT
Times cited: 42
Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience. Clinical advances in hematology & oncology : H&O. 2018 Academic Article GET IT
Times cited: 1
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood advances. 2018 Academic Article GET IT
Times cited: 133
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 5
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018 Information Resource GET IT
Times cited: 912
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood cancer journal. 2017 Article GET IT
Times cited: 15
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2017 Academic Article GET IT
Times cited: 62
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. The Lancet. Oncology. 2017 Academic Article GET IT
Times cited: 147
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 13
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Academic Article GET IT
Times cited: 169
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 12
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Information Resource GET IT
Times cited: 73
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Academic Article GET IT
Times cited: 1325
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017 Academic Article GET IT
Times cited: 59
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. The Journal of molecular diagnostics : JMD. 2017 Academic Article GET IT
Times cited: 78
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 95
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Academic Article GET IT
Times cited: 58
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017 Academic Article GET IT
Times cited: 100
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 23
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Academic Article GET IT
Times cited: 243
The application of mass spectrometry to leukemia drug discovery. Expert opinion on drug discovery. 2016 Editorial Article GET IT
Times cited: 2
Are we ready for precision medicine in acute myeloid leukemia?. Clinical advances in hematology & oncology : H&O. 2016 Article GET IT
Times cited: 1
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. 2016 Academic Article GET IT
Times cited: 321
Clofarabine as a bridge to hematopoietic stem cell transplant. Leukemia & lymphoma. 2016 Article GET IT
Times cited: 5
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 Article GET IT
Times cited: 38
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 157
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature communications. 2016 Academic Article GET IT
Times cited: 29
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 19
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 91
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future oncology (London, England). 2016 Academic Article GET IT
Times cited: 39
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia research. 2015 Academic Article GET IT
Times cited: 30
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia. 2015 Article GET IT
Times cited: 57
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell reports. 2015 Academic Article GET IT
Times cited: 57
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. American journal of hematology. 2015 Academic Article GET IT
Times cited: 29
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2015 Academic Article GET IT
Times cited: 75
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 262
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 146
Mass spectrometry in leukemia research and treatment. Expert review of hematology. 2015 Information Resource GET IT
Times cited: 6
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 32
Evolving treatments in acute myeloid leukemia. Clinical advances in hematology & oncology : H&O. 2015 Article GET IT
Times cited: 1
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 4
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2015 Academic Article GET IT
Times cited: 85
Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium. Clinical advances in hematology & oncology : H&O. 2014 Article GET IT
Times cited: 1
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2014 Academic Article GET IT
Times cited: 101
Epigenetic targeting and personalized approaches for AML. Hematology. American Society of Hematology. Education Program. 2014 Information Resource GET IT
Times cited: 13
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2014 Academic Article GET IT
Times cited: 26
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 80
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 52
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 176
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 2240
Standardizing the initial evaluation for myelodysplastic syndromes. Current hematologic malignancy reports. 2013 Information Resource GET IT
Times cited: 3
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. British journal of haematology. 2013 Academic Article GET IT
Times cited: 24
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 16
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 143
Pregnancy in a woman with chronic neutrophilic leukemia. Obstetrics and gynecology. 2013 Article GET IT
Times cited: 3
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 75
Current treatment of acute myeloid leukemia. Current opinion in oncology. 2012 Information Resource GET IT
Times cited: 124
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 114
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia research. 2012 Information Resource GET IT
Times cited: 52
RBC-transfusion guidelines update. Leukemia research. 2012 Article GET IT
Times cited: 7
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?. Leukemia research. 2012 Academic Article GET IT
Times cited: 9
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2011 Academic Article GET IT
Times cited: 25
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011 Academic Article GET IT
Times cited: 121
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 289
Novel approaches to the treatment of acute myeloid leukemia. Hematology. American Society of Hematology. Education Program. 2011 Information Resource GET IT
Times cited: 81
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leukemia research. 2010 Academic Article GET IT
Times cited: 9
What are RBC-transfusion-dependence and -independence?. Leukemia research. 2010 Article GET IT
Times cited: 88
Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Current hematologic malignancy reports. 2010 Information Resource GET IT
Times cited: 9
Acute myeloid leukemia stem cells: seek and destroy. Expert review of hematology. 2009 Information Resource GET IT
Times cited: 47
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 180
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leukemia & lymphoma. 2009 Academic Article GET IT
Times cited: 56
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 176
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2008 Academic Article GET IT
Times cited: 54
Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow. P & T : a peer-reviewed journal for formulary management. 2008 Academic Article GET IT
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2008 Academic Article GET IT
Times cited: 163
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer. 2008 Academic Article GET IT
Times cited: 50
Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia. Seminars in hematology. 2008 Information Resource GET IT
Times cited: 6
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Academic Article GET IT
Times cited: 55
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia research. 2007 Academic Article GET IT
Times cited: 22
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leukemia research. 2007 Article GET IT
Times cited: 21
Treatment of acute myeloid leukemia in older patients. Expert review of anticancer therapy. 2007 Information Resource GET IT
Times cited: 24
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 Academic Article GET IT
Times cited: 346
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 68
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 24
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 45
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006 Academic Article GET IT
Times cited: 10
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006 Academic Article GET IT
Times cited: 75
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia research. 2006 Article GET IT
Times cited: 25
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 229
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia research. 2003 Academic Article GET IT
Times cited: 22
Hematopoietic growth factors in myelodysplastic syndromes. Current hematology reports. 2003 Information Resource GET IT
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental hematology. 2003 Academic Article GET IT
Times cited: 42
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 26
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 31
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000 Academic Article GET IT
Times cited: 273
Interleukin-5 and the regulation of eosinophil production. Current opinion in hematology. 1999 Information Resource GET IT
Times cited: 58
HIV/AIDS case histories: diagnostic problems. Hodgkin's disease, mixed cellularity type. AIDS patient care and STDs. 1999 Article GET IT
Times cited: 1
Hepatitis C and B-cell lymphoma. AIDS patient care and STDs. 1998 Article GET IT
Times cited: 11
Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture. Journal of neurochemistry. 1994 Academic Article GET IT
Times cited: 41

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Pre-malignant mutation landscape and risk factors for progression to hematologic cancers awarded by National Cancer Institute Co-Investigator 2021 - 2027

more ...

less ...

Background

education and training

M.D., Mount Sinai School of Medicine 1994
B.A., Yale University 1990

Contact

full name

Gail J Roboz

primary email

gar2001@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Gail J Roboz Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage